Essential thrombocythemia (ET) is a myeloproliferative neoplasm (MPN) characterized by thrombocytosis and bone marrow megakaryocytic hyperplasia with the JAK2-V617F mutation in 50-60% of cases. 1 It can progress to myelofibrosis (MF) and rarely to secondary AML. The only curable treatment modality is allogeneic hematopoietic cell transplantation (alloHSCT), especially for transformed disease. We report a patient who progressed to MF with myeloid metaplasia and had prolonged remission with clearing of the JAK2-V617F mutation despite graft failure and autologous reconstitution following an alloHSCT. After disease recurrence, she responded to a subsequent alloHSCT and is in remission.
A 51-year-old woman presented to our bone marrow transplant service for management of advanced stage MPN with MF and pancytopenia, originally classified as ET. The diagnosis of ET was made 10 years prior owing to the incidental finding of thrombocytosis. No bone marrow biopsy was performed; she was treated with anagrelide for 5 years. She developed transfusion-dependent anemia with splenomegaly measuring 26 cm on computerized tomography scan. Bone marrow aspiration and biopsy revealed a MPN with advanced MF with JAK2-V617F mutation positive (PCR amplification and pyrosequencing, RPCI Molecular Diagnostics lab, qualitative assay, sensitivity ⩾ 95%, revised as of 3/2012 to ⩾ 92%). Other molecular testing for BCR-ABL was negative.
Owing to platelet and red cell transfusion dependence, she underwent a matched unrelated peripheral blood stem cell transplant from a female donor (CD34+ cell dose, 11 × 10 6 /kg). Reduced intensity conditioning (RIC) consisted of fludarabine (125 mg/m 2 ) and melphalan (140 mg/m 2 ) and GvHD prophylaxis with a tacrolimus-based regimen. 2 There was a slight increase in ANC on day +13, but it declined and never recovered despite growth factor support. Day +25 bone marrow biopsy demonstrated a hypocellular marrow with hypoplastic hematopoiesis. Non-separated engraftment analysis (AmpFLSTR Profiler Plus PCR Amplification Kit, ThermoFisher Scientific, Waltham, MA, USA, chimerism sensitivity ⩾ 95%) on the bone marrow sample showed mixed myeloid chimerism: 43% donor-related alleles. She did not develop GvHD.
The patient was diagnosed with secondary graft failure, in part due to splenomegaly. She underwent splenic irradiation: 3 Gy on day +31. She remained profoundly pancytopenic requiring full supportive care. She underwent a second RIC peripheral blood alloHSCT from the same donor (CD34+ cell dose, 6.8 × 10
6 /kg) with fludarabine (125 mg/m 2 ) and anti-thymocyte globulin (ATG, 40 mg/kg) conditioning. Post-transplant GvHD prophylaxis consisted of tacrolimus alone. Neutrophils recovered on day +15. She developed serositis secondary to acute GvHD requiring steroid therapy. Day +60 and day +100 bone marrow biopsies showed recovery of hematopoiesis with mild fibrosis. JAK2-V617F mutation was negative. The day +100 peripheral blood chimerism studies showed 100% recipient alleles in both lymphoid and myeloid compartments with undetectable JAK2 mutation (Allele-specific PCR amplification and capillary electrophoresis, Labcorp of America, Raritan, NJ, USA, sensitivity ⩾ 95%).
Despite autologous recovery, the patient remained JAK2-V617F negative in the bone marrow and peripheral blood with mild anemia and thrombocytopenia. At 16 months, the patient developed JAK2 recurrence in the peripheral blood but remained transfusion-independent for another 14 months (Figure 1 ). She developed increasing fatigue and splenomegaly with worsening pancytopenia requiring red cell transfusions. Bone marrow biopsy revealed persistent JAK2-V617F-positive MPN with severe MF. She was initiated on ruxolitinib. The spleen size decreased; however, she had no symptomatic or hematological improvement. She underwent splenectomy with transient blood count improvement but again developed transfusion dependence.
A third matched unrelated peripheral blood RIC alloHSCT using a different donor was performed 45 months after the first transplant (CD34+ cell dose, 5.5 × 10 6 /kg). Conditioning regimen consisted of fludarabine (160 mg/m 2 ), melphalan (75 mg/m 2 ) and TBI (400 cGy). A tacrolimus-based regimen was used for GvHD prophylaxis. 2 Count recovery was noted on Day +16. Day +30 and day +100 bone marrow tests showed hypercellular areas with disorganized trilineage hematopoiesis. Peripheral blood lymphoid and myeloid engraftment showed 100% donor alleles. JAK2 mutation was absent. The patient has done well and remains transfusion-independent 26 months post transplant. She has mild chronic ocular GvHD.
Autologous recovery after secondary graft failure following an alloHSCT is rare. The reported incidence of graft failure after RIC unrelated alloHSCT in MF varies significantly (2-36%). This is due to small patient numbers, differences in patient, disease and donor characteristics and different conditioning regimens. 3, 4 This is the first case describing a prolonged hematologic remission with JAK2-V617F negativity in a MPN treated with alloHSCT resulting in transient engraftment and eventual autologous recovery. Many reports have previously described durable remissions and even cure in a variety of hematological malignancies following autologous reconstitution; most of these cases have been CML transplanted in the chronic phase. [5] [6] [7] [8] [9] Several mechanisms have been advanced to explain this effect, some of which may be applicable to MPN:
1. The anti-leukemic effect of donor lymphocytes is well established. Relapse rates are significantly higher after T cell-depletion of donor lymphocytes. In patients who lose their grafts, an initial donor T cell-mediated graft-versus-tumor effect before graft rejection may be a possible mechanism for achieving anti-tumor response. To study this mechanism further, Maury et al. performed T cell-specific chimerism studies in a patient with a durable CML remission after autologous reconstitution following an allogeneic stem cell transplantation. 8 Though mixed chimerism was found in the peripheral blood in the early period post transplant, they could not demonstrate any residual donor T cells after 4 months. They postulated that donor T cells exert at least a transient GvL effect, sufficient to kill the aberrant clone and lead to prolonged remissions. Transient alloreactivity is most effective when the burden of disease is low pre-transplant. Ballester et al. exploited the intense inflammatory response/ immune response induced by administering HLA mismatched donor lymphocyte infusions (DLI) to seven patients undergoing autologous HSCT for multiple myeloma to produce a graftversus-myeloma effect. 3. In some patients, response is attributed to the high-dose cytotoxic chemotherapy given as part of the myeloablative conditioning regimen. This has been demonstrated by cases of prolonged remissions observed after syngeneic or T celldepleted allogeneic transplants, in which no extensive T cellmediated GvL effect could have occurred. Our patient received a RIC transplant resulting in a decreased anti-cancer effect due to the conditioning. 4. Studies in CML have shown that even in cases where myeloablative regimens are used, non-malignant host-type cells defined as long-term culture initiating cells persist in the bone marrow, which are capable of restoring hematopoiesis. The bone marrow precursor cells have a proliferative advantage over the residual Ph positive cells. 5 We hypothesize that in our patient, the transient GvL effect decreased the JAK2 clone but did not eliminate it. Superior recovery of the normal autologous hematopoiesis when compared with the residual malignant clone led to a prolonged remission and minimal transfusion requirements over the next 2.5 years. Over time, as the GvL effect waned, the malignant clone repopulated the bone marrow and the patient became symptomatic again.
It is possible that the patient had a small JAK2 negative clone that persisted throughout the course of her disease; however, it was only when the JAK2 clone became dominant that she developed symptoms and transfusion requirements. X-chromosomal clonality markers can be used to identify these pre-JAK2 malignant clones, however these tests are not always readily available. 13 Our case also highlights the fact that despite failure to engraft and recurrence of disease, the patient was able to successfully undergo a third alloHSCT after splenectomy. At this time, there is insufficient evidence to support splenectomy as a standard pretransplant procedure, even in those symptomatic patients with massive splenomegaly. The decision needs to be individualized. Reduction in size of spleen with elective use of JAK2 inhibitors pretransplant may improve engraftment rates in such cases.
In conclusion, prolonged hematologic remission is possible in MPN after alloHSCT following secondary graft failure and subsequent autologous reconsitution. Molecular relapse may precede hematologic relapse by several months in such patients. Figure 1 . RBC transfusion trend in relation to JAK2 status and bone marrow transplant. The patient remained transfusion-independent for several months despite redetection of JAK2-V617F in the peripheral blood.
